Optimizing Cholesterol Treatment in Patients With Muscle Complaints

Robert S. Rosenson, Steven Baker, Maciej Banach, Kenneth M. Borow, Lynne T. Braun, Eric Bruckert, Liam R. Brunham, Alberico L. Catapano, Marshall B. Elam, G. B.John Mancini, Patrick M. Moriarty, Pamela B. Morris, Paul Muntner, Kausik K. Ray, Erik S. Stroes, Beth A. Taylor, Valerie H. Taylor, Gerald F. Watts, Paul D. Thompson

Research output: Contribution to journalReview articlepeer-review

Abstract

Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms.

Original languageEnglish
Pages (from-to)1290-1301
Number of pages12
JournalJournal of the American College of Cardiology
Volume70
Issue number10
DOIs
Publication statusPublished - Sep 5 2017

Keywords

  • cardiovascular disease
  • low-density lipoprotein
  • myalgia
  • myopathy
  • statin intolerance

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Optimizing Cholesterol Treatment in Patients With Muscle Complaints'. Together they form a unique fingerprint.

Cite this